Success of Cellnovo’s IPO with €31.6 million raised on Euronext in Paris

Press Release:


Success of Cellnovo’s IPO with €31.6 million raised on Euronext in Paris

  • Offer price set at €10.63 per share
  • Market capitalization of €113.6 million
  • Funds to develop production capabilities and accelerate commercial expansion

Paris, France, July 9, 2015 – Cellnovo Group (« Cellnovo »), a medical technology company that has developed and markets the first connected all-in-one diabetes management system, today announces the success of its Initial Public Offering in compartment C of the Euronext regulated market in Paris ("Euronext Paris"), raising €31.56 million through a capital increase.

The full press release is available on Advent Life Sciences website.

Back